Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-06-15

Clinical Trial Update: AMD 3100 for Treatment of Myelokathexis [Phase 1]

View source ↗

Summary

A Phase 1 trial of AMD 3100 (plerixafor) for neutropenia in WHIM syndrome (myelokathexis); results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMD 3100 (plerixafor)

Snippet

Sponsor: University of Washington | Conditions: Neutropenia | Phase 1 | Status: COMPLETED | Results posted: 2012-06-15